市場調査レポート

商品コード

1403488

前立腺がん診断市場の2030年までの予測：検査タイプ別、がんタイプ別、エンドユーザー別、地域別の世界分析

Prostate Cancer Diagnostics Market Forecasts to 2030 - Global Analysis By Test Type, Cancer Type, End User and by Geography

出版日: 2024年01月01日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,150 595,815円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 753,742円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 911,669円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,076,775円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、世界の前立腺がん診断市場は2023年に87億7,000万米ドルを占め、予測期間中のCAGRは8.23％で成長し、2030年には152億5,000万米ドルに達する見込みです。

前立腺がんを早期段階で特定し説明するために、前立腺がん診断は多面的なアプローチを採用しています。直腸指診（DRE）、経直腸超音波（TRUS）、磁気共鳴画像法（MRI）、前立腺特異抗原（PSA）血液検査は重要な診断技術です。さらに、PSA検査は前立腺から分泌されるタンパク質の量を測定するもので、高値の場合は追加検査の必要性を示すことが多いです。前立腺の大きさや質感の評価には、直腸指診が有効です。

米国国立がん研究所によると、2019年、米国では174,650例以上の前立腺がんが新たに診断されました。さらに、同出典のデータによると、2019年、前立腺がんが原因で31,620例以上が死亡しました。

増加する前立腺がん罹患率

がん検出技術の向上、人口の高齢化、ライフスタイルの変化が、世界中で着実に増加している前立腺がん罹患率の主な原因です。さらに、前立腺がんを初期段階で正確に特定し、特徴付けることができる高度な診断ツールに対するニーズが高まっており、検診プログラムが広く実施されるようになり、ヘルスケアに対する意識が高まるにつれて、市場成長の原動力となっています。

高価な神経画像装置

ヘルスケア施設は、磁気共鳴画像装置（MRI）などの高度なニューロイメージング装置の法外な費用のために、大きな財政的障害に直面しています。特に資源が限られている環境では、最先端の機器の購入と維持に必要な多額の資本支出によって、高度な診断ツールへのアクセスが制限される可能性があります。さらに、この制約を緩和するためには、独創的な資金調達戦略や手頃な価格の代替品が必要となります。

ニューロイメージングの技術開発

ニューロイメージング技術が進歩し続ける限り、市場は大きく成長します。脳磁図（MEG）、陽電子放射断層撮影（PET）、機能的磁気共鳴画像法（fMRI）などの診断技術の進歩は、感度、分解能、診断力を高める機会を提供します。さらに、これらの最先端技術を取り入れるための研究開発に資金を投入することで、正確で綿密な神経画像診断の新たな機会が生まれる可能性があります。

代替診断技術による脅威

従来の神経画像診断は、ウェアラブル神経技術や脳脊髄液バイオマーカー分析のような新たな代替診断技術の脅威にさらされています。さらに、同市場の確立された地位は、非画像診断モダリティからの脅威にさらされているため、関連性を維持し市場シェアを維持するには、継続的なイノベーションと差別化が必要です。

COVID-19の影響：

神経画像診断市場では、COVID-19の流行が大きな影響を及ぼしています。世界の健康危機が突然始まったことで、定期的な診断検査、選択的検診、緊急時以外の受診といったヘルスケアサービスが中断されました。社会的距離を置く措置がとられ、パンデミック管理に資源が割り当てられたため、神経画像診断の利用が減少しました。さらに、ヘルスケア施設の購買能力もサプライチェーンの混乱や経済不安の影響を受け、最先端の画像診断機器の購入が遅れました。

予測期間中、前立腺腺がんセグメントが最大となる見込み

市場シェアが最も大きいセグメントは前立腺腺がんです。診断される前立腺がんの症例の大半は前立腺腺がんです。前立腺の腺房細胞ががんの元の部位であり、臨床的にも攻撃的にもさまざまな形で現れます。年齢、遺伝、ホルモンの影響などは、前立腺腺がんの高い発生率に関連する要因の一つです。さらに、前立腺腺がんは、PSA検査、直腸指診（DRE）、高度な画像技術などの診断技術を用いなければ、診断や特徴づけが困難です。

予測期間中にCAGRが最も高くなると予想されるのは診断検査部門です。

市場において、CAGRが最も高いセグメントは診断検査室です。早期発見の必要性と疾病の蔓延が診断サービスへの需要を高めており、それが診断検査施設の成長を促進しています。これらの施設は、バイオマーカー評価やがんスクリーニングなど、広範な診断検査を提供する上で極めて重要です。また、診断技術の向上や個別化医療の重視により、ヘルスケア環境における診断検査機関の重要性はますます高まっています。

最もシェアの高い地域

前立腺がん診断に関しては、北米が最大の市場シェアを占めています。同地域では前立腺がんが非常に多く、最先端の診断技術が早くから導入されており、ヘルスケアインフラも整っています。さらに、早期発見・診断の確実な手段は、PSA検査のような強固なスクリーニングプログラムです。北米の地位をさらに強固なものにしているのは、がん調査への積極的なアプローチ、政府の強力なバックアップ、一般市民や専門家の意識の高さです。

CAGRが最も高い地域：

前立腺がん診断市場に関しては、アジア太平洋地域のCAGRが最も高いです。前立腺がんの罹患率の上昇、早期発見に関する知識の普及、中国、インド、日本などの国における医療制度の発展などが、この成長を後押ししています。前立腺がんの罹患率上昇の要因となっている同地域の高齢化とライフスタイルの変化により、高度な診断薬へのニーズが高まっています。さらに、政府のイニシアティブ、ヘルスケアへの投資、多国籍診断企業との提携により、最先端の診断技術の採用が加速しています。

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

企業プロファイル
- 追加市場プレイヤーの包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域セグメンテーション
- 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他欧州
アジア太平洋地域
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他アジア太平洋地域
南米
- アルゼンチン
- ブラジル
- チリ
- その他南米
中東とアフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他中東とアフリカ

第9章主な発展

契約、パートナーシップ、コラボレーション、合弁事業
買収と合併
新製品の発売
事業拡大
その他の主要戦略

第10章企業プロファイル

Danaher Corporation
Abbott Laboratories
BioMerieux SA
F. Hoffman La Roche Ltd.
Bayer Aktiengesellschaft
Myriad Genetics Inc.
Genomic Health, Inc.
Agilent Technologies
Siemens Healthcare GmbH
Vyant Bio Inc.
Biocept Inc.
DiaSorin S.p.A
AstraZeneca Plc.
OPKO Health, Inc.
Becton Dickinson and Company
MDx Health
Foundation Medicine Inc.
Telo Genomics Corp（3D Signatures）

図表

List of Tables

Table 1 Global Prostate Cancer Diagnostics Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Prostate Cancer Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
Table 3 Global Prostate Cancer Diagnostics Market Outlook, By Preliminary Tests (2021-2030) ($MN)
Table 4 Global Prostate Cancer Diagnostics Market Outlook, By PSA Tests (2021-2030) ($MN)
Table 5 Global Prostate Cancer Diagnostics Market Outlook, By Free PSA Test (2021-2030) ($MN)
Table 6 Global Prostate Cancer Diagnostics Market Outlook, By Total PSA Test (2021-2030) ($MN)
Table 7 Global Prostate Cancer Diagnostics Market Outlook, By Other Preliminary Tests (2021-2030) ($MN)
Table 8 Global Prostate Cancer Diagnostics Market Outlook, By Confirmatory Tests (2021-2030) ($MN)
Table 9 Global Prostate Cancer Diagnostics Market Outlook, By Pca3 Test (2021-2030) ($MN)
Table 10 Global Prostate Cancer Diagnostics Market Outlook, By Trans-Rectal Ultrasound (2021-2030) ($MN)
Table 11 Global Prostate Cancer Diagnostics Market Outlook, By Biopsy Test (2021-2030) ($MN)
Table 12 Global Prostate Cancer Diagnostics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
Table 13 Global Prostate Cancer Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
Table 14 Global Prostate Cancer Diagnostics Market Outlook, By Cancer Type (2021-2030) ($MN)
Table 15 Global Prostate Cancer Diagnostics Market Outlook, By Benign Prostatic Hyperplasia (2021-2030) ($MN)
Table 16 Global Prostate Cancer Diagnostics Market Outlook, By Prostatic Adenocarcinoma (2021-2030) ($MN)
Table 17 Global Prostate Cancer Diagnostics Market Outlook, By Small Cell Carcinoma (2021-2030) ($MN)
Table 18 Global Prostate Cancer Diagnostics Market Outlook, By Other Cancer Types (2021-2030) ($MN)
Table 19 Global Prostate Cancer Diagnostics Market Outlook, By End User (2021-2030) ($MN)
Table 20 Global Prostate Cancer Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
Table 21 Global Prostate Cancer Diagnostics Market Outlook, By Outpatient Facilities (2021-2030) ($MN)
Table 22 Global Prostate Cancer Diagnostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
Table 23 Global Prostate Cancer Diagnostics Market Outlook, By Cancer Research Institutes (2021-2030) ($MN)
Table 24 Global Prostate Cancer Diagnostics Market Outlook, By Home Care (2021-2030) ($MN)
Table 25 Global Prostate Cancer Diagnostics Market Outlook, By Research & Manufacturing (2021-2030) ($MN)
Table 26 Global Prostate Cancer Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
Table 27 North America Prostate Cancer Diagnostics Market Outlook, By Country (2021-2030) ($MN)
Table 28 North America Prostate Cancer Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
Table 29 North America Prostate Cancer Diagnostics Market Outlook, By Preliminary Tests (2021-2030) ($MN)
Table 30 North America Prostate Cancer Diagnostics Market Outlook, By PSA Tests (2021-2030) ($MN)
Table 31 North America Prostate Cancer Diagnostics Market Outlook, By Free PSA Test (2021-2030) ($MN)
Table 32 North America Prostate Cancer Diagnostics Market Outlook, By Total PSA Test (2021-2030) ($MN)
Table 33 North America Prostate Cancer Diagnostics Market Outlook, By Other Preliminary Tests (2021-2030) ($MN)
Table 34 North America Prostate Cancer Diagnostics Market Outlook, By Confirmatory Tests (2021-2030) ($MN)
Table 35 North America Prostate Cancer Diagnostics Market Outlook, By Pca3 Test (2021-2030) ($MN)
Table 36 North America Prostate Cancer Diagnostics Market Outlook, By Trans-Rectal Ultrasound (2021-2030) ($MN)
Table 37 North America Prostate Cancer Diagnostics Market Outlook, By Biopsy Test (2021-2030) ($MN)
Table 38 North America Prostate Cancer Diagnostics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
Table 39 North America Prostate Cancer Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
Table 40 North America Prostate Cancer Diagnostics Market Outlook, By Cancer Type (2021-2030) ($MN)
Table 41 North America Prostate Cancer Diagnostics Market Outlook, By Benign Prostatic Hyperplasia (2021-2030) ($MN)
Table 42 North America Prostate Cancer Diagnostics Market Outlook, By Prostatic Adenocarcinoma (2021-2030) ($MN)
Table 43 North America Prostate Cancer Diagnostics Market Outlook, By Small Cell Carcinoma (2021-2030) ($MN)
Table 44 North America Prostate Cancer Diagnostics Market Outlook, By Other Cancer Types (2021-2030) ($MN)
Table 45 North America Prostate Cancer Diagnostics Market Outlook, By End User (2021-2030) ($MN)
Table 46 North America Prostate Cancer Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
Table 47 North America Prostate Cancer Diagnostics Market Outlook, By Outpatient Facilities (2021-2030) ($MN)
Table 48 North America Prostate Cancer Diagnostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
Table 49 North America Prostate Cancer Diagnostics Market Outlook, By Cancer Research Institutes (2021-2030) ($MN)
Table 50 North America Prostate Cancer Diagnostics Market Outlook, By Home Care (2021-2030) ($MN)
Table 51 North America Prostate Cancer Diagnostics Market Outlook, By Research & Manufacturing (2021-2030) ($MN)
Table 52 North America Prostate Cancer Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
Table 53 Europe Prostate Cancer Diagnostics Market Outlook, By Country (2021-2030) ($MN)
Table 54 Europe Prostate Cancer Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
Table 55 Europe Prostate Cancer Diagnostics Market Outlook, By Preliminary Tests (2021-2030) ($MN)
Table 56 Europe Prostate Cancer Diagnostics Market Outlook, By PSA Tests (2021-2030) ($MN)
Table 57 Europe Prostate Cancer Diagnostics Market Outlook, By Free PSA Test (2021-2030) ($MN)
Table 58 Europe Prostate Cancer Diagnostics Market Outlook, By Total PSA Test (2021-2030) ($MN)
Table 59 Europe Prostate Cancer Diagnostics Market Outlook, By Other Preliminary Tests (2021-2030) ($MN)
Table 60 Europe Prostate Cancer Diagnostics Market Outlook, By Confirmatory Tests (2021-2030) ($MN)
Table 61 Europe Prostate Cancer Diagnostics Market Outlook, By Pca3 Test (2021-2030) ($MN)
Table 62 Europe Prostate Cancer Diagnostics Market Outlook, By Trans-Rectal Ultrasound (2021-2030) ($MN)
Table 63 Europe Prostate Cancer Diagnostics Market Outlook, By Biopsy Test (2021-2030) ($MN)
Table 64 Europe Prostate Cancer Diagnostics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
Table 65 Europe Prostate Cancer Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
Table 66 Europe Prostate Cancer Diagnostics Market Outlook, By Cancer Type (2021-2030) ($MN)
Table 67 Europe Prostate Cancer Diagnostics Market Outlook, By Benign Prostatic Hyperplasia (2021-2030) ($MN)
Table 68 Europe Prostate Cancer Diagnostics Market Outlook, By Prostatic Adenocarcinoma (2021-2030) ($MN)
Table 69 Europe Prostate Cancer Diagnostics Market Outlook, By Small Cell Carcinoma (2021-2030) ($MN)
Table 70 Europe Prostate Cancer Diagnostics Market Outlook, By Other Cancer Types (2021-2030) ($MN)
Table 71 Europe Prostate Cancer Diagnostics Market Outlook, By End User (2021-2030) ($MN)
Table 72 Europe Prostate Cancer Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
Table 73 Europe Prostate Cancer Diagnostics Market Outlook, By Outpatient Facilities (2021-2030) ($MN)
Table 74 Europe Prostate Cancer Diagnostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
Table 75 Europe Prostate Cancer Diagnostics Market Outlook, By Cancer Research Institutes (2021-2030) ($MN)
Table 76 Europe Prostate Cancer Diagnostics Market Outlook, By Home Care (2021-2030) ($MN)
Table 77 Europe Prostate Cancer Diagnostics Market Outlook, By Research & Manufacturing (2021-2030) ($MN)
Table 78 Europe Prostate Cancer Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
Table 79 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Country (2021-2030) ($MN)
Table 80 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
Table 81 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Preliminary Tests (2021-2030) ($MN)
Table 82 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By PSA Tests (2021-2030) ($MN)
Table 83 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Free PSA Test (2021-2030) ($MN)
Table 84 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Total PSA Test (2021-2030) ($MN)
Table 85 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Other Preliminary Tests (2021-2030) ($MN)
Table 86 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Confirmatory Tests (2021-2030) ($MN)
Table 87 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Pca3 Test (2021-2030) ($MN)
Table 88 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Trans-Rectal Ultrasound (2021-2030) ($MN)
Table 89 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Biopsy Test (2021-2030) ($MN)
Table 90 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
Table 91 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
Table 92 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Cancer Type (2021-2030) ($MN)
Table 93 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Benign Prostatic Hyperplasia (2021-2030) ($MN)
Table 94 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Prostatic Adenocarcinoma (2021-2030) ($MN)
Table 95 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Small Cell Carcinoma (2021-2030) ($MN)
Table 96 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Other Cancer Types (2021-2030) ($MN)
Table 97 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By End User (2021-2030) ($MN)
Table 98 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
Table 99 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Outpatient Facilities (2021-2030) ($MN)
Table 100 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
Table 101 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Cancer Research Institutes (2021-2030) ($MN)
Table 102 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Home Care (2021-2030) ($MN)
Table 103 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Research & Manufacturing (2021-2030) ($MN)
Table 104 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
Table 105 South America Prostate Cancer Diagnostics Market Outlook, By Country (2021-2030) ($MN)
Table 106 South America Prostate Cancer Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
Table 107 South America Prostate Cancer Diagnostics Market Outlook, By Preliminary Tests (2021-2030) ($MN)
Table 108 South America Prostate Cancer Diagnostics Market Outlook, By PSA Tests (2021-2030) ($MN)
Table 109 South America Prostate Cancer Diagnostics Market Outlook, By Free PSA Test (2021-2030) ($MN)
Table 110 South America Prostate Cancer Diagnostics Market Outlook, By Total PSA Test (2021-2030) ($MN)
Table 111 South America Prostate Cancer Diagnostics Market Outlook, By Other Preliminary Tests (2021-2030) ($MN)
Table 112 South America Prostate Cancer Diagnostics Market Outlook, By Confirmatory Tests (2021-2030) ($MN)
Table 113 South America Prostate Cancer Diagnostics Market Outlook, By Pca3 Test (2021-2030) ($MN)
Table 114 South America Prostate Cancer Diagnostics Market Outlook, By Trans-Rectal Ultrasound (2021-2030) ($MN)
Table 115 South America Prostate Cancer Diagnostics Market Outlook, By Biopsy Test (2021-2030) ($MN)
Table 116 South America Prostate Cancer Diagnostics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
Table 117 South America Prostate Cancer Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
Table 118 South America Prostate Cancer Diagnostics Market Outlook, By Cancer Type (2021-2030) ($MN)
Table 119 South America Prostate Cancer Diagnostics Market Outlook, By Benign Prostatic Hyperplasia (2021-2030) ($MN)
Table 120 South America Prostate Cancer Diagnostics Market Outlook, By Prostatic Adenocarcinoma (2021-2030) ($MN)
Table 121 South America Prostate Cancer Diagnostics Market Outlook, By Small Cell Carcinoma (2021-2030) ($MN)
Table 122 South America Prostate Cancer Diagnostics Market Outlook, By Other Cancer Types (2021-2030) ($MN)
Table 123 South America Prostate Cancer Diagnostics Market Outlook, By End User (2021-2030) ($MN)
Table 124 South America Prostate Cancer Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
Table 125 South America Prostate Cancer Diagnostics Market Outlook, By Outpatient Facilities (2021-2030) ($MN)
Table 126 South America Prostate Cancer Diagnostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
Table 127 South America Prostate Cancer Diagnostics Market Outlook, By Cancer Research Institutes (2021-2030) ($MN)
Table 128 South America Prostate Cancer Diagnostics Market Outlook, By Home Care (2021-2030) ($MN)
Table 129 South America Prostate Cancer Diagnostics Market Outlook, By Research & Manufacturing (2021-2030) ($MN)
Table 130 South America Prostate Cancer Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
Table 131 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Country (2021-2030) ($MN)
Table 132 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
Table 133 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Preliminary Tests (2021-2030) ($MN)
Table 134 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By PSA Tests (2021-2030) ($MN)
Table 135 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Free PSA Test (2021-2030) ($MN)
Table 136 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Total PSA Test (2021-2030) ($MN)
Table 137 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Other Preliminary Tests (2021-2030) ($MN)
Table 138 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Confirmatory Tests (2021-2030) ($MN)
Table 139 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Pca3 Test (2021-2030) ($MN)
Table 140 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Trans-Rectal Ultrasound (2021-2030) ($MN)
Table 141 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Biopsy Test (2021-2030) ($MN)
Table 142 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
Table 143 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
Table 144 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Cancer Type (2021-2030) ($MN)
Table 145 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Benign Prostatic Hyperplasia (2021-2030) ($MN)
Table 146 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Prostatic Adenocarcinoma (2021-2030) ($MN)
Table 147 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Small Cell Carcinoma (2021-2030) ($MN)
Table 148 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Other Cancer Types (2021-2030) ($MN)
Table 149 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By End User (2021-2030) ($MN)
Table 150 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
Table 151 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Outpatient Facilities (2021-2030) ($MN)
Table 152 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
Table 153 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Cancer Research Institutes (2021-2030) ($MN)
Table 154 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Home Care (2021-2030) ($MN)
Table 155 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Research & Manufacturing (2021-2030) ($MN)
Table 156 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)

Product Code: SMRC24713

According to Stratistics MRC, the Global Prostate Cancer Diagnostics Market is accounted for $8.77 billion in 2023 and is expected to reach $15.25 billion by 2030 growing at a CAGR of 8.23% during the forecast period. In order to identify and describe prostate cancer in its early stages, prostate cancer diagnostics employ a multifaceted approach. Digital rectal examination (DRE), transrectal ultrasound (TRUS), magnetic resonance imaging (MRI), and the prostate-specific antigen (PSA) blood test are important diagnostic techniques. Moreover, the PSA test gauges the amount of a protein secreted by the prostate gland; high levels frequently signal the need for additional research. The evaluation of the prostate's size and texture is aided by a digital rectal examination.

According to the National Cancer Institute, in 2019, over 174,650 new cases of prostate cancer were diagnosed in the U.S. Additionally, data from the same source also suggests that over 31,620 deaths occurred in 2019 due to prostate cancer.

Market Dynamics:

Driver:

Growing prostate cancer incidence

Improved cancer detection techniques, aging populations, and altered lifestyles are the main causes of the prostate cancer incidence that has been rising steadily throughout the world. Furthermore, there is a growing need for sophisticated diagnostic tools that can precisely identify and characterize prostate cancer at its earliest stages, which is driving market growth as screening programs become more widely implemented and healthcare awareness increases.

Restraint:

Expensive neuroimaging equipment

Healthcare facilities face a major financial obstacle due to the prohibitive cost of sophisticated neuroimaging equipment, such as magnetic resonance imaging (MRI) machines. Access to advanced diagnostic tools may be restricted by the significant capital outlay necessary for purchasing and maintaining state-of-the-art machinery, especially in environments with limited resources. Additionally, it will take creative financing strategies and affordable substitutes to lessen this constraint.

Opportunity:

Technological developments in neuroimaging

The market is poised for substantial growth as long as neuroimaging technologies continue to progress. Advancements in diagnostic techniques like magnetoencephalography (MEG), positron emission tomography (PET), and functional magnetic resonance imaging (fMRI) present opportunities for increased sensitivity, resolution, and diagnostic power. Furthermore, putting money into research and development to incorporate these state-of-the-art technologies can lead to new opportunities for precise and thorough neuroimaging diagnosis.

Threat:

Threats from alternative diagnostic technologies

Traditional neuroimaging diagnostics are under threat from emerging alternative diagnostic technologies like wearable neurotechnology and cerebrospinal fluid biomarker analysis. Moreover, the market's established position is under threat from non-imaging modalities, so continued innovation and differentiation are necessary to stay relevant and hold onto market share.

COVID-19 Impact:

In the neuroimaging diagnostics market, the COVID-19 pandemic has had a significant effect. Healthcare services, such as regular diagnostic tests, elective screenings, and non-emergency medical visits, were disrupted by the abrupt start of the global health crisis. The application of social distancing measures and the allocation of resources to pandemic management led to a decrease in the use of neuroimaging diagnostics. Furthermore, healthcare facilities ability to make purchases was also impacted by supply chain disruptions and economic uncertainty, which caused delays in the purchase of cutting-edge imaging equipment.

The Prostatic Adenocarcinoma segment is expected to be the largest during the forecast period

The segment with the largest market share is prostate adenocarcinoma. The majority of cases of prostate cancer that are diagnosed are prostatic adenocarcinoma, which is the most common type of the disease. The prostate's glandular cells are the cancer's original site, and it can present in a variety of ways, both clinically and aggressively. Age, heredity, and hormonal influences are among the factors linked to the high incidence of prostatic adenocarcinoma. Moreover, prostatic adenocarcinoma is difficult to diagnose and characterize without the use of diagnostic techniques such as PSA testing, digital rectal examination (DRE), and advanced imaging technologies.

The Diagnostic Laboratories segment is expected to have the highest CAGR during the forecast period

In the market, the segment with the highest CAGR is diagnostic laboratories. The need for early detection and rising disease prevalence are driving up demand for diagnostic services, which in turn is fueling the growth of diagnostic laboratories. These establishments are crucial in offering an extensive array of diagnostic examinations, such as biomarker evaluations and cancer screenings. Additionally, diagnostic laboratories are becoming increasingly important in the healthcare environment as a result of improvements in diagnostic technologies and a focus on personalized medicine.

Region with largest share:

Concerning prostate cancer diagnostics, North America holds the largest market share. Prostate cancer is very common in the area; cutting-edge diagnostic technologies were adopted early; and the region has a strong healthcare infrastructure. Furthermore, a reliable means of early detection and diagnosis is through robust screening programs, like PSA testing. Further strengthening North America's position is proactive approaches to cancer research, robust government backing, and high levels of public and professional awareness.

Region with highest CAGR:

In terms of the market for prostate cancer diagnostics, the Asia-Pacific region has the highest CAGR. The rising incidence of prostate cancer, growing knowledge of early detection, and the development of the healthcare system in nations like China, India, and Japan are some of the reasons driving this growth. The need for sophisticated diagnostics is being driven by the region's aging population and changing lifestyles, which are factors in the rising incidence of prostate cancer. Additionally, the adoption of cutting-edge diagnostic technologies is being accelerated by government initiatives, healthcare investments, and partnerships with multinational diagnostic companies.

Key players in the market:

Some of the key players in Prostate Cancer Diagnostics market include Danaher Corporation, Abbott Laboratories, BioMerieux SA, F. Hoffman La Roche Ltd., Bayer Aktiengesellschaft, Myriad Genetics Inc., Genomic Health, Inc., Agilent Technologies, Siemens Healthcare GmbH, Vyant Bio Inc., Biocept Inc., DiaSorin S.p.A, AstraZeneca Plc., OPKO Health, Inc., Becton Dickinson and Company, MDx Health, Foundation Medicine Inc. and Telo Genomics Corp (3D Signatures).

Key Developments:

In December 2023, Danaher Corp., a global life sciences and diagnostics provider based in Washington D.C., has completed its $5.7 billion acquisition of Abcam plc, a supplier of protein research tools for life sciences based in Cambridge, England. Abcam has become an indirect wholly owned subsidiary of Danaher. Danaher's Life Sciences businesses provide tools and technologies to support the advancement of pharmaceuticals and biopharmaceuticals.

In December 2023, Roche announced the entry into a definitive merger agreement to acquire Carmot Therapeutics, Inc., a privately owned US company based in Berkeley, California. Carmot's R&D portfolio includes clinical stage subcutaneous and oral incretins with best-in-class potential to treat obesity in patients with and without diabetes, as well as a number of preclinical programs.

In September 2023, Abbott has entered a definitive agreement for the acquisition of Bigfoot Biomedical, which develops smart insulin management systems for individuals with diabetes. Together, the companies have worked on connected diabetes solutions since 2017. Developed by Bigfoot Biomedical, Bigfoot Unity is a smart insulin management system. It features connected insulin pen caps that use integrated continuous glucose monitoring (iCGM) data and healthcare provider instructions.

Test Types Covered:

Preliminary Tests
Confirmatory Tests
Immunohistochemistry
Other Test Types

Cancer Types Covered:

Benign Prostatic Hyperplasia
Prostatic Adenocarcinoma
Small Cell Carcinoma
Other Cancer Types

End Users Covered:

Hospitals
Outpatient Facilities
Diagnostic Laboratories
Cancer Research Institutes
Home Care
Research & Manufacturing
Other End Users

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Prostate Cancer Diagnostics Market, By Test Type

5.1 Introduction
5.2 Preliminary Tests
- 5.2.1 PSA Tests
- 5.2.2 Free PSA Test
- 5.2.3 Total PSA Test
- 5.2.4 Other Preliminary Tests
5.3 Confirmatory Tests
- 5.3.1 Pca3 Test
- 5.3.2 Trans-Rectal Ultrasound
- 5.3.3 Biopsy Test
5.4 Immunohistochemistry
5.5 Other Test Types

6 Global Prostate Cancer Diagnostics Market, By Cancer Type

6.1 Introduction
6.2 Benign Prostatic Hyperplasia
6.3 Prostatic Adenocarcinoma
6.4 Small Cell Carcinoma
6.5 Other Cancer Types

7 Global Prostate Cancer Diagnostics Market, By End User

7.1 Introduction
7.2 Hospitals
7.3 Outpatient Facilities
7.4 Diagnostic Laboratories
7.5 Cancer Research Institutes
7.6 Home Care
7.7 Research & Manufacturing
7.8 Other End Users

8 Global Prostate Cancer Diagnostics Market, By Geography

8.1 Introduction
8.2 North America
- 8.2.1 US
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 Italy
- 8.3.4 France
- 8.3.5 Spain
- 8.3.6 Rest of Europe
8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 New Zealand
- 8.4.6 South Korea
- 8.4.7 Rest of Asia Pacific
8.5 South America
- 8.5.1 Argentina
- 8.5.2 Brazil
- 8.5.3 Chile
- 8.5.4 Rest of South America
8.6 Middle East & Africa
- 8.6.1 Saudi Arabia
- 8.6.2 UAE
- 8.6.3 Qatar
- 8.6.4 South Africa
- 8.6.5 Rest of Middle East & Africa

9 Key Developments

9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies

10 Company Profiling

10.1 Danaher Corporation
10.2 Abbott Laboratories
10.3 BioMerieux SA
10.4 F. Hoffman La Roche Ltd.
10.5 Bayer Aktiengesellschaft
10.6 Myriad Genetics Inc.
10.7 Genomic Health, Inc.
10.8 Agilent Technologies
10.9 Siemens Healthcare GmbH
10.10 Vyant Bio Inc.
10.11 Biocept Inc.
10.12 DiaSorin S.p.A
10.13 AstraZeneca Plc.
10.14 OPKO Health, Inc.
10.15 Becton Dickinson and Company
10.16 MDx Health
10.17 Foundation Medicine Inc.
10.18 Telo Genomics Corp (3D Signatures)